Share this story
Close X
Switch to Desktop Site

When patents kill: Genzyme's patent-protected, life-saving drug

(Read article summary)

Genzyme / Business Wire

(Read caption) Scientists work at Genzyme Corp.'s Science Center in Framingham, Mass., a central site for early stage research. Genzyme holds the patent on a medication that it can't produce enough of to meet demand, but which it won't license to other manufacturers.

About these ads

As noted by Mike Masnick on Techdirt (post reprinted below), due to the monopoly granted by patent (yes, it is a monopoly), people are literally dying because Fabrazyme is in short supply and the sole, monopolistic manufacturer, Genzyme, can’t make enough quickly enough–and no one else is permitted to make it due to the patent. I’m sure the intellectual propergandists will callously, arrogantly, and smugly retort that without patents, Genzyme would never have invented the drug in the first place, and instead of, oh, 5,000 people dying, 20,000 would die. So saving 15,000 (I’m guessing at the numbers) is better than none, right? So the ones who die have no complaint about the patent system, since without it they’d die anyway. What a chilling mentality; and of course there is no reason to think drugs would not be invented absent patents.


Page 1 of 6

Follow Stories Like This
Get the Monitor stories you care about delivered to your inbox.